Under the terms of the collaboration, Direvo will apply its proprietary protein-engineering capabilities to create specifically engineered proteases. MedImmune will then be responsible for the development and marketing of the protease product that may arise under the agreement.
Direvo will receive undisclosed upfront and milestone payments, as well as research funding plus royalties on potential sales of the therapeutic protease should it reach the market.
Thomas von Ruden, CEO of Direvo, said: “We are very happy to partner this internally initiated research project. This collaboration is a further technical and commercial validation for Direvo’s proven world-class technology-platform for the generation of optimized proteases as novel biopharmaceuticals.”